CD274 and ovarian carcinoma: Succeeding research is necessary to certify the effectiveness of checkpoint immune inhibitors therapy in ovarian cancer, as well as to appraise the perspective role of anti-PDL-1 blockers, especially regarding the treatment of high grade malignant epithelial ovarian tumors, such as the clear-cell and mucinous carcinoma histological subtypes [56,82].